{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:39:24Z","timestamp":1759451964914,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T00:00:00Z","timestamp":1569110400000},"content-version":"am","delay-in-days":356,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009634","name":"Susan G. Komen Foundation\u2019s Career Catalyst Research","doi-asserted-by":"publisher","award":["CCR15329745"],"award-info":[{"award-number":["CCR15329745"]}],"id":[{"id":"10.13039\/100009634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-17-1-0189"],"award-info":[{"award-number":["W81XWH-17-1-0189"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society Institutional Research","doi-asserted-by":"publisher","award":["IRG-97-219-14"],"award-info":[{"award-number":["IRG-97-219-14"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medicine","doi-asserted-by":"crossref","award":["P30GM103331"],"award-info":[{"award-number":["P30GM103331"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.vaccine.2018.09.010","type":"journal-article","created":{"date-parts":[[2018,9,12]],"date-time":"2018-09-12T12:52:44Z","timestamp":1536756764000},"page":"6262-6269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17\/Th1 T cell response against unglycosylated MUC1 antigen"],"prefix":"10.1016","volume":"36","author":[{"given":"Rebecca K.","family":"Carrell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca A.","family":"Stanton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen P.","family":"Ethier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda C.","family":"LaRue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam C.","family":"Soloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2018.09.010_b0005","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrc3322","article-title":"Paths to stemness: building the ultimate antitumour T cell","volume":"12","author":"Gattinoni","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2018.09.010_b0010","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.coi.2010.01.001","article-title":"Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)","volume":"22","author":"Simpson","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0015","doi-asserted-by":"crossref","first-page":"234","DOI":"10.4049\/jimmunol.1102034","article-title":"Comprehensive analysis of CD4+ T cells in the decision between tolerance and immunity in vivo reveals a pivotal role for ICOS","volume":"189","author":"Lischke","year":"2012","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0020","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ni.1690","article-title":"The costimulatory molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T helper cells and TH-17 cells","volume":"10","author":"Bauquet","year":"2009","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0025","doi-asserted-by":"crossref","first-page":"55ra78","DOI":"10.1126\/scitranslmed.3000448","article-title":"The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells","volume":"2","author":"Paulos","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2018.09.010_b0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2007-11-120998","article-title":"Tumor-specific Th17-polarized cells eradicate large established melanoma","volume":"112","author":"Muranski","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.09.010_b0035","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.immuni.2009.09.014","article-title":"T helper 17 cells promote cytotoxic T cell activation in tumor immunity","volume":"31","author":"Martin-Orozco","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2018.09.010_b0040","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1080\/21645515.2016.1165908","article-title":"Adenoviral vector-based strategies against infectious disease and cancer","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2018.09.010_b0045","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nrc1122","article-title":"Occurrence of leukaemia following gene therapy of X-linked SCID","volume":"3","author":"Kohn","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.vaccine.2018.09.010_b0050","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.4049\/jimmunol.179.3.1721","article-title":"Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses","volume":"179","author":"Lor\u00e9","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0055","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/sj.cgt.7700894","article-title":"Comparison of recombinant adenovirus and synthetic peptide for DC-based melanoma vaccination","volume":"13","author":"Steitz","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.vaccine.2018.09.010_b0060","first-page":"1954","article-title":"Tissue-specific Expression of a Human Polymorphic Epithelial Mucin (MUC1) in Transgenic Mice","author":"Peat","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.09.010_b0065","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1002\/eji.200839130","article-title":"Adenovirus 5- and 35-based immunotherapy enhances the strength but not breadth or quality of immunity during chronic SIV infection","volume":"39","author":"Soloff","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0070","doi-asserted-by":"crossref","first-page":"658","DOI":"10.4049\/jimmunol.1301904","article-title":"Novel mechanisms underlying the immediate and transient global tolerization of splenic dendritic cells after vaccination with a self-antigen","volume":"192","author":"Farkas","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0075","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.4049\/jimmunol.178.5.2787","article-title":"Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th\/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells","volume":"178","author":"Turner","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0080","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu009","article-title":"Massive mobilization of dendritic cells in H5N1 influenza virus infection of nonhuman primates","author":"Soloff","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2018.09.010_b0085","doi-asserted-by":"crossref","first-page":"W147","DOI":"10.1093\/nar\/gkw419","article-title":"Heatmapper: web-enabled heat mapping for all","volume":"44","author":"Babicki","year":"2016","journal-title":"Nucl Acids Res"},{"key":"10.1016\/j.vaccine.2018.09.010_b0090","first-page":"315","article-title":"Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model","author":"Rowse","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.09.010_b0095","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.1158\/0008-5472.CAN-09-4519","article-title":"Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses","volume":"70","author":"Ryan","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2018.09.010_b0100","first-page":"15286","article-title":"Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin","volume":"265","author":"Gendler","year":"1990","journal-title":"J Biol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0105","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory T cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2018.09.010_b0110","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00262-015-1712-6","article-title":"Anti-PD-L1 prolongs survival and triggers T cell but not humoral anti-tumor immune responses in a human MUC1-expressing preclinical ovarian cancer model","volume":"64","author":"Mony","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.vaccine.2018.09.010_b0115","doi-asserted-by":"crossref","first-page":"774","DOI":"10.4049\/jimmunol.180.2.774","article-title":"ICOS controls the pool size of effector-memory and regulatory T cells","volume":"180","author":"Burmeister","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/j.immuni.2011.09.019","article-title":"Th17 cells are long lived and retain a stem cell-like molecular signature","volume":"35","author":"Muranski","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2018.09.010_b0125","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2013-10-535245","article-title":"ICOS-based chimeric antigen receptors program bipolar TH17\/TH1 cells","volume":"124","author":"Guedan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.09.010_b0130","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1401082","article-title":"The inducible costimulator augments Tc17 cell responses to self and tumor tissue","author":"Nelson","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00281-009-0191-2","article-title":"Th17 cytokines and vaccine-induced immunity","volume":"32","author":"Lin","year":"2010","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cell.2012.02.034","article-title":"Antibody-based immunotherapy of cancer","volume":"148","author":"Weiner","year":"2012","journal-title":"cell"},{"key":"10.1016\/j.vaccine.2018.09.010_b0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.molimm.2009.11.018","article-title":"Balb\/c EGFP mice are tolerant against immunization utilizing recombinant adenoviral-based vectors encoding EGFP: a novel model for the study of tolerance mechanisms and vaccine efficacy","volume":"47","author":"Steitz","year":"2010","journal-title":"Mol Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0150","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood-2005-07-2955","article-title":"Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency","volume":"107","author":"Warnatz","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2018.09.010_b0155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/35051107","article-title":"ICOS is critical for CD40-mediated antibody class switching","volume":"409","author":"McAdam","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.09.010_b0160","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35051113","article-title":"ICOS is essential for effective T-helper-cell responses","volume":"409","author":"Tafuri","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2018.09.010_b0165","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/nyas.12108","article-title":"Preventing cancer by targeting abnormally expressed self-antigens: MUC1 vaccines for prevention of epithelial adenocarcinomas","volume":"1284","author":"Beatty","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2018.09.010_b0170","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0065-230X(00)79007-5","article-title":"Biochemistry and pathological importance of mucin-associated antigens in gastrointestinal neoplasia","volume":"79","author":"Baldus","year":"2000","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.vaccine.2018.09.010_b0175","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0180","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00002371-200009000-00007","article-title":"Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer","volume":"23","author":"Scholl","year":"2000","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2018.09.010_b0185","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.vaccine.2018.09.010_b0190","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1073\/pnas.2432220100","article-title":"A glycopeptide in complex with MHC class I uses the GalNAc residue as an anchor","volume":"100","author":"Apostolopoulos","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2018.09.010_b0195","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1084\/jem.20020493","article-title":"Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells","volume":"196","author":"Vlad","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2018.09.010_b0200","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0968-0896(98)00092-3","article-title":"Effects of glycosylation on fragments of tumour associated human epithelial mucin MUC1","volume":"6","author":"Braun","year":"1998","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.vaccine.2018.09.010_b0205","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1002\/anie.201509935","article-title":"A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer","volume":"55","author":"Palitzsch","year":"2016","journal-title":"Angew Chem - Int Ed"},{"key":"10.1016\/j.vaccine.2018.09.010_b0210","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1002\/anie.201300390","article-title":"Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid","volume":"52","author":"Cai","year":"2013","journal-title":"Angew Chem - Int Ed"},{"key":"10.1016\/j.vaccine.2018.09.010_b0215","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1002\/anie.201104529","article-title":"Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues","volume":"50","author":"Gaidzik","year":"2011","journal-title":"Angew Chem - Int Ed"},{"key":"10.1016\/j.vaccine.2018.09.010_b0220","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/glycob\/cwj044","article-title":"Chemoenzymatically synthesized multimeric Tn\/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance","volume":"16","author":"S\u00f8rensen","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2018.09.010_b0225","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/glycob\/cwl061","article-title":"Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat","volume":"17","author":"Tarp","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.vaccine.2018.09.010_b0230","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a National Cancer Institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.vaccine.2018.09.010_b0235","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/eji.201343718","article-title":"Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells","volume":"44","author":"Church","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0240","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.4049\/jimmunol.175.10.6551","article-title":"The cooperation between two CD4 T cells induces tumor protective immunity in MUC.1 transgenic mice","volume":"175","author":"Gerloni","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coi.2017.07.004","article-title":"Vaccines targeting helper T cells for cancer immunotherapy","volume":"47","author":"Melssen","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2018.09.010_b0250","first-page":"1","article-title":"Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy","author":"Amatore","year":"2018","journal-title":"Expert Opin Ther Targets"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831257X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1831257X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:28:26Z","timestamp":1759400906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1831257X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":50,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0264410X1831257X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.010","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17\/Th1 T cell response against unglycosylated MUC1 antigen","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2018.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}